There's no single "best" GLP-1 — the right choice depends on your health, your goals, and a conversation with a prescriber. This tool won't pick one for you. Tick what matters to you and it will show you how the FDA-approved options line up on that — and hand you a tailored list ofquestions to ask your clinician. Nothing you tick leaves your device.
What matters to you?
Tick any that apply — the comparison and your question list update as you go.
This is not a recommendation. It shows how the approved options differ on what you care about — it can't see your health history, other medicines, or what you'll tolerate. Which one (if any) is right for you is a decision for you and your clinician. Highlighting shows only which options are FDA-approved or studied for what you selected — not which is right for you.
One thing every option shares: all three commonly cause nausea and other gut side effects, especially in the first weeks, and a minority of people can't tolerate them.Tolerability — not just the average number — is usually what decides which one actually works for you.
Semaglutide GLP-1
~15% avg, 1 trial*
Weight-management brand
Wegovy
Diabetes brand
Ozempic · Rybelsus
How you take it
Weekly injection (or a daily pill)
The weight brand Wegovy is also FDA-approved to lower cardiovascular risk. Comes as a weekly shot and, now, a daily pill.
Approved or studied for what you selected:
Tirzepatide GLP-1 + GIP (dual)
~20% avg, 1 trial*
Weight-management brand
Zepbound
Diabetes brand
Mounjaro
How you take it
Weekly injection
Averages come from separate trials (not a head-to-head), and a higher average can also come with more GI side effects — the option you tolerate and stay on is what matters most. That said, in its own trial tirzepatide had the highest average loss of the three. Zepbound is also FDA-approved for obstructive sleep apnea.
Approved or studied for what you selected:
Orforglipron GLP-1
~11% avg, 1 trial*
Weight-management brand
Foundayo
Diabetes brand
—
How you take it
Daily pill
The newest option and the first non-peptide (small-molecule) GLP-1 pill approved for weight management (2026). Notably, it can be taken any time, with no food or water restrictions. (An oral form of semaglutide is also approved.)
Approved or studied for what you selected:
*Average % body-weight loss in each drug's main obesity trial (semaglutide STEP 1, tirzepatide SURMOUNT-1, orforglipron ATTAIN-1). Separate trials, not head-to-head, and an average is not a prediction for any one person. Full detail + sources: GLP-1 medicines compared.
Questions to bring to your clinician
These apply to everyone considering a GLP-1 — tick what matters to you above to add tailored questions.
I’d prefer a pill — is an oral option (orforglipron/Foundayo, or the oral form of semaglutide) a good fit for me, and how do its expected results and side effects compare to an injection?
I have type 2 diabetes — would a diabetes-indicated version (e.g. Ozempic/Rybelsus or Mounjaro) make more sense for me than a weight-management brand, and what does that mean for my coverage?
Given my heart-risk profile, is a medicine with a proven cardiovascular-risk-reduction indication (semaglutide/Wegovy) worth prioritising?
I have obstructive sleep apnea — is tirzepatide/Zepbound (which is FDA-approved for OSA) worth considering in my case?
How should I weigh a higher average weight loss against tolerability, cost, and my own situation — knowing a trial average isn’t a prediction for me, and the biggest average isn’t automatically the best fit?
What will each option actually cost me on my insurance, and are there savings programs — or an appeal route — if it’s denied?
Given my health history and the other medicines I take, which of these would you steer me toward or away from — and why?
Is there anything in my history — thyroid cancer (medullary/MEN 2), a past bout of pancreatitis, or the possibility of pregnancy — that would make any of these a bad idea for me?
What side effects are most likely for me, and what's the plan if I don't tolerate the first choice?